Cancer Test Maker Grail Starts Trading After Spin-Off From Illumina At $18.35 Per Share
Portfolio Pulse from Benzinga Newsdesk
Cancer test maker Grail has started trading at $18.35 per share after being spun off from Illumina.
June 25, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Grail has started trading at $18.35 per share after its spin-off from Illumina. This marks a significant milestone for the company as it becomes an independent entity.
The spin-off and subsequent trading of Grail at $18.35 per share is a significant event, likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Illumina has completed the spin-off of Grail, which is now trading at $18.35 per share. This move allows Illumina to focus on its core business while potentially benefiting from Grail's future success.
The successful spin-off of Grail allows Illumina to streamline its operations and focus on its core business, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80